Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV
- Conditions
- VaricellaJapanese Encephalitis
- Interventions
- Biological: Varicella VaccineBiological: JE-CV Vaccine
- Registration Number
- NCT01190228
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Brief Summary
The aim of the study is to investigate the memory immune response and the yearly persistence of the immunity against Japanese Encephalitis (JE) after vaccination with Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in participants previously vaccinated with JE-CV vaccine.
Objectives:
* To describe JE immune status before and after JE-CV vaccination in subjects previously vaccinated with JE-CV vaccine
* To describe the immune status before and after JE-CV vaccination in JE-naïve control subjects.
* To describe the safety (in terms of solicited and unsolicited adverse events) of a single dose of JE-CV vaccine up to 6 months after the last vaccination.
* To describe all related serious adverse events (SAEs) and related deaths from 6 months to 5 years after vaccination in JE-CV-primed subjects.
- Detailed Description
Study participants who are previously immunized with JE-CV vaccine will receive a booster dose of the JE-CV vaccine and will be followed up for 5 years for immunogenicity.
The control (JE-CV naïve) participants will receive either one dose of JE-CV vaccine or one dose of varicella vaccine.
All participants will be monitored for safety for 6 month post-vaccination.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 454
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group 3: Varicella Vaccine Varicella Vaccine JE-CV vaccine naïve participants will receive one dose of Varicella vaccine on Day 0. Group 1: JE-CV Vaccine Booster JE-CV Vaccine Participants previously vaccinated with JE-CV vaccine will receive a booster dose of JE-CV vaccine on Day 0. Group 2: JE-CV Vaccine First Dose JE-CV Vaccine JE-CV vaccine naïve participants will receive a single dose of JE-CV vaccine on Day 0.
- Primary Outcome Measures
Name Time Method Summary of Geometric Mean Titer of JE Virus Antibodies Before and Up to 5 Years Following a Booster Dose of Live Attenuated JE-CV Day 0 (pre-vaccination) and Days 7 and 28 and Year 1, 2, 3, 4, and 5 post-vaccination The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay.
Summary of Geometric Mean Titer Ratios of JE Virus Antibodies Up to 5 Years Following a Booster Dose of Live Attenuated JE-CV Year 1, 2, 3, 4, and 5 post-vaccination The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay.
Percentage of Participants With JE Seroprotection Before and Following a Dose of Live Attenuated JE-CV Day 0 (pre-vaccination) and Day 7 and Day 28 post-vaccination The presence of JE virus neutralizing antibodies was measured using a 50% plaque reduction neutralization test (PRNT50). Seroprotection status for antibody levels against JE virus before (on Day 0) and after JE-CV vaccination (Day 7 and Day 28) was defined as neutralizing antibody titer ≥ 10 (1/dilution).
Summary of Serological Flavivirus Status at Baseline of Participants Vaccinated With a Dose of Live Attenuated JE-CV Day 0 (pre-vaccination) The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay. Flavivirus positive was defined as titers against JE virus ≥10 (1/dilution) or titers against at least 1 dengue serotype ≥10 (1/dilution). Flavivirus negative was defined as titers against JE virus \<10 (1/dilution) and titers against the 4 dengue serotypes \<10 (1/dilution).
Percentage of Participants With JE Seroconversion Following a Dose of Live Attenuated JE-CV Vaccine Day 0 (pre-vaccination) and Day 7 and Day 28 post-vaccination The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay. Seroconversion was defined as participants with a pre-vaccination titer \<10 (1/dilution) and post-vaccination titer ≥10 (1/dilution, or participants with pre vaccination titer ≥10 (1/dilution) and a ≥4-fold increase from pre- to post-vaccination.
Summary of Geometric Mean Titers of JE Virus Antibodies Following a Dose of Live Attenuated JE-CV Day 0 (pre-vaccination) and Day 7 and Day 28 post-vaccination The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay.
Percentage of Participants With JE Seroprotection Before and Up to 5 Years Following a Booster Dose of Live Attenuated JE-CV Day 0 (pre-vaccination) and Days 7 and 28, and Year 1, 2, 3, 4, and 5 post-vaccination The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay. Seroprotection status for antibody levels against JE virus before (on Day 0) and after JE-CV vaccination (Days 7 and 28 and Years 1, 2, 3, 4, and 5) was defined as neutralizing antibody titer ≥ 10 (1/dilution).
Summary of Geometric Mean Titer Ratios of JE Virus Antibodies Following a Dose of Live Attenuated JE-CV Day 0 (pre-vaccination) and Day 7 and Day 28 post-vaccination The presence of JE virus neutralizing antibodies was measured using a PRNT50 assay.
Number of Participants With Solicited Injection-Site Reactions and Systemic Reactions Following a Dose of Live Attenuated JE-CV or Varicella Vaccine Day 0 up to Day 14 post-vaccination Injection-site reactions: Pain, Erythema, and Swelling. Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3 Injection-site reactions: Pain, Incapacitating, unable to perform usual activities. Erythema and Swelling, ≥5 cm. Grade 3 Systemic reactions: Fever, 39.0°C; Headache, Malaise, and Myalgia, Significant; prevents daily activities.
- Secondary Outcome Measures
Name Time Method